Predict your next investment

Corporation
HEALTHCARE | Biotechnology
ipierian.com

See what CB Insights has to offer

Founded Year

2007

Stage

Acquired | Acquired

Total Raised

$95.67M

Valuation

$0000 

About iPierian

iPierian is a biotechnology company developing therapies for neurodegenerative disease, specifically focused on discovering monoclonal antibodies against targets of the Tau protein for treatment of Alzheimer's disease and other tauopathies (e.g. progressive supranuclear palsy, frontotemporal dementia). The company's lead antibody, IPN007, represents a new approach to Alzheimer's by targeting a novel form of secreted Tau protein that is differentially regulated in Alzheimer's disease patients, to slow the spread of Tau throughout the brain and therefore inhibit the associated disease progression. iPierian's monoclonal antibody program for Tau is based on novel Tau discoveries made using the company's proprietary induced pluripotent stem cell (iPSC) technology.

iPierian Headquarter Location

951 Gateway Boulevard

South San Francisco, California, 94080,

United States

650-872-4700

Latest iPierian News

Bristol Flips Remnants of Adnexus, iPierian to Roche, Biogen For $470M

Apr 13, 2017

XconomyNew York —  Priorities change over time for drugmakers, as evidenced today by Bristol-Myers Squibb. The company announced two separate deals for experimental drugs that no longer fit its strategy—both of which were remnants of old acquisitions and a past plan to zero in on genetic diseases. In one deal, Bristol (NYSE: BMY ) has sent Biogen (NASDAQ: BIIB ), of Cambridge, MA, an experimental drug (BMS-986168) for a neurological disease called progressive supranuclear palsy (PSP). Bristol gets $300 million up front from Biogen in this deal, with another $410 million in possible future payments if the drug progresses. PSP is a devastating, rare neurodegenerative disease that causes problems walking and thinking and leads to other significant health problems, like pneumonia. There are no effective treatments. This attracted Bristol, which acquired the drug when it bought South San Francisco-based iPerian for $175 million up front in 2014 . Bristol’s R&D chief Francis Cuss noted in a statement at the time the company was zeroing in on “genetically defined diseases” where patients had limited options. iPierian’s drug is designed to stop a form of the protein Tau called “eTau” from spreading from neuron to neuron in the brain. In acquiring the PSP drug, Biogen is also now on the hook for any remaining payments due to the stockholders of iPierian, which include Kleiner Perkins Caufield & Byers, MPM Capital, GV (formerly known as Google Ventures), and SR One. Bristol’s latest annual report, filed in February , shows the company owed another $554 million in contingent payments tied to the iPierian deal. The drug just began Phase 2 testing, with results expected in 2019, according to clinicaltrials.gov . (Prior to the acquisition, meanwhile, iPierian split itself in two—the rest of the company became True North Therapeutics , which remains independent.) Another drug Bristol was developing under its genetic disease plan was a therapy acquired in a 2007 buyout of Adnexus Therapeutics. Bristol paid $415 million for Adnexus, of Waltham, MA, , a company that had been developing biologic drugs derived from the protein fibronectin. One experimental drug to come from that work was BMS-986089, a drug for Duchenne muscular dystrophy, a progressive muscle disease that puts patients in wheelchairs by their teens and often kills them at a young age from heart and lung complications. Swiss pharma giant Roche is buying BMS-986089, a drug that blocks myostatin, a protein implicated in muscle growth, for $170 million up front. BMS-986089 also recently began mid-stage testing, according to clinicaltrials.gov , and Bristol is one of several companies—among them Pfizer, Regeneron Pharmaceuticals, and Novartis—developing myostatin-blocking drugs to treat Duchenne and other diseases. Bristol could get another $205 million in downstream payments and royalties if the drug ever reaches the market. Combined, the PSP and Duchenne drugs were the only two in Bristol’s pipeline targeting genetic diseases. The drugmaker is now far more focused on cancer, where it is one of the leaders in immunotherapy, and immunology, where it has been building up a pipeline of drugs targeting fibrosis and the liver disease nonalcoholic steatohepatitis, among other disorders. Bristol’s most recent buyouts, among them Padlock Therapeutics , Flexus Biosciences , Nitto Denko, and Cormorant Pharmaceuticals , all fit within these areas. “Licensing these assets to Biogen and Roche will enable Bristol-Myers Squibb to prioritize the other promising opportunities for asset development that have advanced across our diversified portfolio,” said Mike Burgess, Bristol’s head of cardiovascular, fibrosis and immunoscience. Ben Fidler is Xconomy's Deputy Biotechnology Editor. You can e-mail him at bfidler@xconomy.com Follow @benthefidler

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing iPierian

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

iPierian is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

iPierian Patents

iPierian has filed 16 patents.

The 3 most popular patent topics include:

  • Cognitive disorders
  • Dementia
  • Proteins
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/14/2014

9/3/2019

Monoclonal antibodies, Proteins, Molecular biology, Small nuclear RNA, Immune system

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/14/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/3/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Monoclonal antibodies, Proteins, Molecular biology, Small nuclear RNA, Immune system

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.